Key facts
- This page summarizes Neera Clase's Form 4 filing for Tarsus Pharmaceuticals, Inc. (TARS).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 05 Nov 2026, 16:40.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Award
Additional SEC filing notes
Footnote F1
25% of the option shares shall vest on November 1, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
Footnote F2
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
Footnote F3
The RSUs will vest in four equal annual installments on December 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.